Investigating the effect of the AIRVO on arterial carbon dioxide (PaCO2) in patients with stable Chronic Obstructive Pulmonary Disease (COPD).
Completed
- Conditions
- Chronic Obstructive Pulmonary DiseaseRespiratory - Chronic obstructive pulmonary disease
- Registration Number
- ACTRN12615000471583
- Lead Sponsor
- Medical Research Institute of New Zealand
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 48
Inclusion Criteria
1. A doctor’s diagnosis of COPD
2. Age greater than or equal to 40 years
Exclusion Criteria
1.Smoking pack year history <10 years
2.FEV1/FVC >70%
3.Long term oxygen therapy
4.COPD not deemed to be ‘stable’:
a.Current exacerbation requiring acute treatment with short course antibiotic/oral steroid or oxygen therapy.
b.Hospital admission for an acute exacerbation of COPD in the last 6 weeks.
5.Nasal conditions such as deviated septum, chronic rhinitis, current cold/flu which, in the evaluation by the investigator, could impair nasal breathing.
6.Any other condition, which at the investigator’s discretion, is believed may present a safety risk or impact the feasibility of the study or study results.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in transcutaneous carbon dioxide (PtCO2) from baseline,* as measured by a small heated transcutaneous probe which attaches painlessly to the earlobe.<br><br>*baseline is the measurement taken at t=0 at the start of each intervention[20 minutes]
- Secondary Outcome Measures
Name Time Method